Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
113 EUR | +0,62% | +4,24% | +4,73% |
24/04 | IPSEN : Q1 beter dan verwacht; verwachtingen ongewijzigd | |
24/04 | Transcript : Ipsen S.A., Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024 |
Vakgebied
- oncologie (75,1%);
- neurowetenschap (21,1%);
- zeldzame ziekten (3,7%).
Eind 2023 had de groep 4 onderzoeks- en ontwikkelingscentra in Frankrijk, het Verenigd Koninkrijk, de Verenigde Staten en China, en 4 productiesites wereldwijd.
De geografische verdeling van de omzet is als volgt: Europa (40,2%), Noord-Amerika (33,3%) en andere (26,5%).
Aantal werknemers: 5 325
Verkoop per activiteit
EUR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Oncology
75,2
%
| 2 380 | 78,7 % | 2 351 | 75,2 % | -1,19% |
Neurosciences
21,1
%
| 604 | 20,0 % | 659 | 21,1 % | +9,08% |
Rare Diseases
3,7
%
| 41 | 1,4 % | 117 | 3,7 % | +184,43% |
Verkoop per regio
EUR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Europe
40,2
%
| 1 237 | 40,9 % | 1 257 | 40,2 % | +1,56% |
North America
33,3
%
| 1 032 | 34,1 % | 1 042 | 33,3 % | +0,94% |
Rest of the World
26,5
%
| 756 | 25,0 % | 829 | 26,5 % | +9,73% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Loew
CEO | Chief Executive Officer | 57 | 01-07-20 |
Director of Finance/CFO | 54 | 03-11-14 | |
Chairman | 66 | 22-11-10 | |
Sandra Silvestri
CTO | Chief Tech/Sci/R&D Officer | 50 | 05-05-23 |
Chief Tech/Sci/R&D Officer | 57 | 22-09-23 | |
Aidan Murphy
CTO | Chief Tech/Sci/R&D Officer | 58 | 01-01-18 |
Craig Marks
IRC | Investor Relations Contact | - | - |
Corporate Officer/Principal | - | 01-03-22 | |
Corporate Officer/Principal | - | 01-10-20 | |
Corporate Officer/Principal | 50 | 01-11-21 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Karen Witts
BRD | Director/Board Member | 61 | 21-01-22 |
Michèle Ollier
BRD | Director/Board Member | 65 | 27-05-15 |
Chairman | 66 | 22-11-10 | |
Henri Beaufour
BRD | Director/Board Member | 59 | 30-08-05 |
Antoine Flochel
BRD | Director/Board Member | 59 | 30-08-05 |
Carol Xueref
BRD | Director/Board Member | 67 | 01-06-12 |
Piet Wigerinck
BRD | Director/Board Member | 58 | 01-05-18 |
David Loew
CEO | Chief Executive Officer | 57 | 01-07-20 |
Director/Board Member | 44 | 06-11-20 | |
Naomi Binoche
BRD | Director/Board Member | - | - |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 83 814 526 | 34 798 107 ( 41,52 %) | 1 116 316 ( 1,332 %) | 41,52 % |
Participaties
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Ipsen Pharma SAS
Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. |
Pharmaceuticals: Major
|
Ipsen Pharma Biotech SAS
Ipsen Pharma Biotech SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma Biotech SAS engages in the pharmaceutical industry. It offers drugs to treat neurology, endocrinology, uro-oncology, hematology, gastroenterology, cardiovascular, and cognitive disorders. The company is headquartered in Signes, France. |
Pharmaceuticals: Major
|
Socapharma SAS
|
Sector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+4,73% | 9,96 mld. | |
+25,83% | 661 mld. | |
+27,00% | 566 mld. | |
-6,76% | 352 mld. | |
+20,34% | 332 mld. | |
+3,00% | 283 mld. | |
+13,09% | 231 mld. | |
+5,46% | 200 mld. | |
-9,61% | 195 mld. | |
-6,26% | 145 mld. |